Biotinylated Human HLA-A*24:02&B2M&NY-ESO-1 (LLMWITQCF) Complex Protein (Monomer, MALS verified)

NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A24 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*2402 NY-ESO-1 (LLMWITQCF) complex protein is a complex of HLA-A*2402 of the MHC Class I, B2M and LLMWITQCF peptide of the NY-ESO-1.

Biotinylated Human HLA-A*24:02&B2M&NY-ESO-1 (LLMWITQCF) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 35.8 kDa and 11.7 kDa. The protein migrates as 38-42 kDa and <14 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Immobilized Biotinylated Human HLA-A*24:02&B2M&NY-ESO-1 (LLMWITQCF) Complex Protein (Cat. No. HL1-H82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-1 ng/mL (QC tested).